0XI8 Stock Chart & Stats
€125.06
€0.00(0.00%)
At close: 4:00 PM EDT
€125.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€125.06 - €125.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€19.66B
Enterprise Value€22.19K
Total Cash (Recent Filing)€482.30M
Total Debt (Recent Filing)€2.04B
Price to Earnings (P/E)28.4
BetaN/A
Next Earnings
Nov 11, 2026EPS Estimate
2.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.20
Shares Outstanding97,500,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€236.24Price Target Upside88.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)9.7
Revenue Forecast (FY)€5.53B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthSteris’s extremely low trailing leverage (debt/equity ~0.03) and improved ROE (~11%) provide durable financial flexibility. This capital structure supports sustained shareholder returns, tuck-in M&A, and investments in manufacturing without materially increasing financial risk over the next 2–6 months.
Cash GenerationExceptional FY2026 free cash flow (~$983M) and ~72% conversion of net income into FCF demonstrate reliable cash generation. That durable cash production funds capex, dividends and the $1B buyback plan, supporting capital allocation even if near-term FCF moderates.
Recurring, Diversified Revenue BaseSteris’s installed-base model—capital equipment placements that drive repeat consumables and service revenue—plus balanced growth across Healthcare, AST and Life Sciences creates recurring, less cyclical cash flows. This structural mix supports margin resilience and predictable revenues over time.
Bears Say
Tariff HeadwindOngoing tariff exposure (~$60–65M modeled for FY2027) is a structural cost headwind that compresses margins unless fully offset by pricing or productivity. Persistent tariffs reduce operating leverage and constrain sustainable margin expansion over the medium term.
Moderating Free Cash FlowManagement’s FY2027 FCF guide (~$850M) implies a meaningful step-down versus FY2026, driven by higher capex, working capital and one-time items. Lower structural FCF limits excess capital for buybacks or opportunistic M&A and requires stricter prioritization of investments and returns.
AST Demand & Inventory CyclicalityAST service softness and med-tech customers’ inventory reductions introduce demand volatility into a material segment. This structural cyclicality can cause uneven revenue and operating-profit swings, complicating forecasting and margin sustainability across planning horizons.
Steris News
0XI8 FAQ
What was Steris plc’s price range in the past 12 months?
Steris plc lowest share price was €125.06 and its highest was €125.06 in the past 12 months.
What is Steris plc’s market cap?
Steris plc’s market cap is €19.66B.
When is Steris plc’s upcoming earnings report date?
Steris plc’s upcoming earnings report date is Nov 11, 2026 which is in 87 days.
How were Steris plc’s earnings last quarter?
Steris plc released its earnings results on Aug 05, 2026. The company reported €2.243 earnings per share for the quarter, beating the consensus estimate of €2.161 by €0.082.
Is Steris plc overvalued?
According to Wall Street analysts Steris plc’s price is currently Undervalued.
Does Steris plc pay dividends?
Steris plc does not currently pay dividends.
What is Steris plc’s EPS estimate?
Steris plc’s EPS estimate is 2.33.
How many shares outstanding does Steris plc have?
Steris plc has 97,500,110 shares outstanding.
What happened to Steris plc’s price movement after its last earnings report?
Steris plc reported an EPS of €2.243 in its last earnings report, beating expectations of €2.161. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Steris plc?
Currently, no hedge funds are holding shares in GB:0XI8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€236.24 (88.90% Upside)
€236.24 (88.90% Upside)
Blogger Sentiment
Bullish
GB:0XI8 Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.79%
12-Months-Change
Fundamentals
Return on Equity
1.20%
Trailing 12-Months
Asset Growth
3.18%
Trailing 12-Months
Company Description
Steris plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
0XI8 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive financial and operational picture: STERIS delivered a record fiscal 2026 with double-digit adjusted EPS growth, exceptional free cash flow (~$983M), stronger leverage (gross debt/EBITDA ~1.2x), and multiple segment milestones (Healthcare, AST, Life Sciences). Management provided constructive FY2027 guidance (7–8% revenue growth, EPS up ~9–11%, modest margin expansion) while continuing shareholder returns (dividend increase, $1B buyback authorization) and strategic investments (manufacturing consolidation, tuck-in M&A, AI for service). Offsetting these positives are tangible near-term headwinds: tariff costs (~$60–65M annual spend with no refunds assumed), higher effective tax rates due to withholding and geographic mix, Q4 margin compression, AST service softness and inventory-led demand variability, and a forecasted reduction in free cash flow for FY2027. Overall, the highlights — record growth, strong cash generation, prudent capital allocation, and constructive guidance — outweigh the lowlights, which are manageable but notable operational and tax/tariff risks.View all GB:0XI8 earnings summaries0XI8 Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland
0XI8 Stock 12 Month Forecast
Average Price Target
€236.24
▲(88.90% Upside)
Technical Analysis
Dexcom
―
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―